[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mycophenolate-mofetil\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mycophenolate-mofetil":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100559777","phase-4-reduced-immunosuppression-in-older-renal-transplant-recipients-with-trugraftrac-monitoring-riot-trial-a-prospective-randomized-multicenter-trial-100559777",false,"NCT06568549","Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®\u002FTRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.","Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf® Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.","RIOT","Inclusion Criteria:\n\n* Solitary kidney transplant recipient \\>55 years of age. At most 1 prior solitary kidney transplant.\n* No other solid organ transplant though recipients of autologous stem cell transplants are eligible.\n* HIV negative.\n* Subjects must be on tacrolimus and mycophenolate mofetil or Myfortic at the time of consent. Prednisone at the time of consent is optional and is per local standard of care. Patients randomized to MMF withdrawal will be placed on prednisone 5mg\u002Fd at 4 months. Use of other immunosuppression medications for maintenance (cyclosporine, azathioprine, belatacept, sirolimus) is excluded.\n\nExclusion Criteria:\n\nTime of Transplant Exclusion Criteria:\n\n* The results of the most recent DSA testing indicate DSA with an MFI \\>2000.\n* The results of the most recent cPRA testing indicate cPRA is above \\>80% (based on MFI \\>2000).\n\n  4-Month Exclusion Criteria:\n* Acute rejection episode either clinical or on biopsy (greater than borderline). Subjects must not experience any type of rejection episodes from the time of transplant and must not show any signs of rejection (Cellular or Antibody mediated rejection, excluding borderline) at their 4-month biopsy (If obtained per standard of care). Subjects experiencing rejection will not be eligible for randomization and MMF withdrawal.\n* De novo DSA\n* Subjects who are not on tacrolimus at the time of randomization will be placed in the non-randomized group.\n* Subjects who at the time of or prior to randomization were maintained on mycophenolate mofetil or Myfortic and have had their medication held or temporarily discontinued due to clinical indications (toxicity to the medication, polyoma virus infections, cancer, etc.) remain eligible for randomization.\n* Has a history of an underlying clinically significant acute or chronic medical condition or physical examination findings which, in the opinion of the investigator, would make study participation not in the participants best interest (e.g., compromise the well-being) or that could prevent, or limit the protocol-specified assessment.",true,"ALL","55 Years",{"count":21,"type":22},350,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The purpose of this research is to determine the safety and efficacy of withdrawing MMF (Mycophenolate Mofetil) in kidney transplant recipients who are 55 years or older at the time of receiving a kidney transplant. We are comparing them to patients who receive the standard of care Mycophenolate Mofetil.",[28,29],"Kidney Transplantation","Mycophenolate Mofetil",[31],"Kidney Transplant","RECRUITING","2026-03-18",{"date":35,"type":36},"2026-03-20","ACTUAL",{"date":38,"type":36},"2025-06-13",{"date":40,"type":22},"2031-03-31",{"name":42,"class":43},"Mayo Clinic","OTHER",3,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":18,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100512366","mycophenolate-mofetil-in-gastrointestinal-henoch-schonlein-purpura-100512366","NCT05951517","Mycophenolate Mofetil in Gastrointestinal Henoch-Schonlein Purpura","The Clinical Study of Mycophenolate Mofetil in Pediatric Refractory Gastrointestinal Henoch-Schonlein Purpura","Inclusion Criteria:\n\n1. Ages range from 3 to 18 years old;\n2. Patients who meet the diagnostic criteria for HSP and involve the digestive tract: acute diffuse abdominal colic, including intussusception and gastrointestinal bleeding, appears during the course of the disease or is found on physical examination;\n3. Refractory gastrointestinal type HSP: treated with Intravenous corticosteroid 2 mg\u002Fkg\u002Fd for 3 days without effecacy or relapsed during the attenuation of corticosteroid\n4. Parents or guardians agree to treatment and sign a written informed consent form.\n\nExclusion Criteria:\n\n1. Patients who are allergic to MMF;\n2. Patients with severe diseases: such as systemic malignancies, heart failure, liver and renal failure, Immune deficiency, severe infectious diseases, organ transplant surgery, or other current indications for emergency surgery;\n3. Patients with other digestive system diseases;\n4. Those who have previously used MMF clinical trials;\n5. Other situations the researcher thought inappropriate to participate in the study.","3 Years","18 Years",{"count":55,"type":22},24,[57],"NA","Henoch Schönlein purpura (HSP) is the most common type of vasculitis in children, with an incidence of \\~10\u002F100,000, whereas \\>90% of the patients develop symptoms at \\\u003C10 years of age. Although HSP is generally a self-limiting disease, it may also lead to severe complications, such as intestinal intussusception, infarction and perforation, as well as end-stage renal disease. The management of HSP includes symptomatic treatment and immunosuppressive therapy in certain patients. Previous retrospective studies have reported that most patients with gastrointestinal (GI) symptoms may benefit from early usage of glucocorticoid, whereas there are still a part of HSP patients with GI did not achieved remission after administering of steroid. Therefore, the aim of the present study was to investigate the clinical features of refractory GI HSP and the clinical outcome of mycophenolate mofetil in these patients.",[60,61,29],"Henoch-Schönlein Purpura","Gastrointestinal Injury",[63,64,65,66,67],"Allergic purpura","complications,","renal involvement","gastrointestinal involvement","mycophenolate mofetil","2023-07-18",{"date":70,"type":36},"2023-07-19",{"date":72,"type":36},"2023-01-01",{"date":74,"type":22},"2026-12-31",{"name":76,"class":43},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",1]